首页> 外文期刊>Journal of vascular and interventional radiology: JVIR >Is a Technetium-99m Macroaggregated Albumin Scan Essential in the Workup for Selective Internal Radiation Therapy with Yttrium-90? An Analysis of 532 Patients
【24h】

Is a Technetium-99m Macroaggregated Albumin Scan Essential in the Workup for Selective Internal Radiation Therapy with Yttrium-90? An Analysis of 532 Patients

机译:是一种技术-99M大型大型白蛋白扫描在yttrium-90的选择性内部放射疗法的工程中必需吗? 532例患者分析

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Purpose To determine if baseline patient, tumor, and pretreatment evaluation characteristics could help identify patients who require technetium-99m ( 99m Tc) macroaggregated albumin ( 99m Tc MAA) imaging before selective internal radiation therapy (SIRT). Materials and Methods In this retrospective analysis, 532 consecutive patients with primary (n?= 248) or metastatic (n?= 284) liver tumors were evaluated between 2006 and 2015. Variables were compared between patients in whom 99m Tc MAA imaging results contraindicated/modified SIRT administration with yttrium-90 ( 90 Y) resin microspheres and those who were treated as initially planned. The 99m Tc MAA findings that contraindicated/modified SIRT were a lung shunt fraction (LSF) > 20%, gastrointestinal 99m Tc MAA uptake, or a mismatch between 99m Tc MAA uptake and intrahepatic tumor distribution. Results LSF > 20% and gastrointestinal MAA uptake were observed in 7.5% and 3.9% of patients, respectively, and 11% presented a mismatch. Presence of a single lesion (odds ratio [OR]?= 2.4) and vascular invasion (OR?= 5.5) predicted LSF > 20%, and GI MAA uptake was predicted by the presence of liver metastases (OR?= 3.7) and 99m Tc MAA injection through the common/proper hepatic artery (OR?= 4.7). Vascular invasion (OR?= 4.1) was the only predictor of LSF > 20%?and/or?GI?MAA?uptake (sensitivity?= 49.2%, specificity?= 80.3%, negative predictive value?= 92.4%). Previous antiangiogenic treatment (OR?= 2.4) and presence of a single lesion (OR?= 2.6) predicted mismatch. Conclusions Imaging with 99m Tc MAA is essential in SIRT workup because baseline characteristics may not adequately predict 99m Tc MAA results. Nevertheless, the absence of vascular invasion potentially identifies a group of patients at low risk of SIRT contraindication/modification in whom performing SIRT in a single session (ie, pretreatment evaluation and SIRT on the same day) should be explored. ]]>
机译:摘要目的,以确定基线患者,肿瘤和预处理评估特征是否有助于识别在选择性内部放射治疗(SIRT)之前需要Technetium-99M(99M TC)大型蛋白酶(99M TC MAA)成像的患者。在该回顾性分析中,在2006年至2015年间评估了532名患有初级(n = 248)或转移性(n = 284)肝肿瘤的532名患者。在99米TC MAA成像结果禁止的患者之间比较变量/用钇-90(90 y)树脂微球的改性SIRT施用,并按照初步策划的人进行治疗。 99M TC MAA发现,禁忌/改性SIRT是一种肺部分流级分(LSF)> 20%,胃肠道99M TC MAA吸收,或99mM TC的吸收和肝内肿瘤分布之间的错配。结果在7.5%和3.9%的患者分别观察到LSF> 20%和胃肠道MAA摄取,11%提出了不匹配。单个病变的存在(几率比[或] = 2.4)和血管侵袭(或?= 5.5)预测LSF> 20%,并且通过存在肝转移(或α= 3.7)和99米来预测GI MAA摄取通过常见/适当的肝动脉注射TC MAA(或?= 4.7)。血管入侵(或?= 4.1)是LSF> 20%的唯一预测因子​​?和/或?GI?MAA?摄取(敏感性?= 49.2%,特异性?= 80.3%,阴性预测值?= 92.4%)。先前的抗血管生成(或?= 2.4)和单个病变(或?= 2.6)的存在预测不匹配。结论99M TC MAA的成像在SIRT工作中至关重要,因为基线特性可能无法充分预测99M TC MAA结果。然而,缺乏血管侵袭可能会识别一组低风险的患者禁忌/修改的低风险,在单一的会议中表演SIRT(即同一天的预处理评估和调味汁)。 ]]>

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号